Triplet Therapy Including Belamaf Prolongs Survival in Multiple Myeloma
By Elana Gotkine HealthDay Reporter
FRIDAY, Feb. 9, 2024 -- For patients with relapsed or refractory multiple myeloma (RRMM), triplet therapy of belantamab mafodotin (belamaf) plus bortezomib and dexamethasone (BVd) improves outcomes, with an acceptable safety profile, according to a study presented during the February 2024 session of the American Society for Clinical Oncology Plenary Series.
Maria-Victoria Mateos, Ph.D., from the Hospital Universitario de Salamanca in Spain, and colleagues conducted a randomized, phase III head-to-head trial to examine the efficacy and safety of BVd versus triplet standard-of-care therapy (daratumumab, bortezomib, and dexamethasone [DVd]) for patients with RRMM. A total of 494 patients with one or more prior lines of therapy were randomly allocated to BVd or DVd (243 and 251, respectively); the primary end point was independent review committee-assessed progression-free survival (PFS).
The researchers found that the median PFS was 36.6 and 13.4 months in the BVd and DVd arms, respectively, after a median follow-up of 28.2 months (hazard ratio, 0.41). Overall survival data were 29 percent mature; median overall survival was not reached in either arm (hazard ratio, 0.57). The overall response rate was 82.7 and 71.3 percent for BVd and DVd, respectively. All patients experienced one or more adverse event; 90 and 67 percent of patients, respectively, in the BVd and DVd arms reported grade 3/4 treatment-related adverse events, and 50 and 37 percent, respectively, reported serious adverse events.
"The DREAMM-7 findings demonstrate that BVd improved outcomes for patients with relapsed or refractory multiple myeloma while also having a manageable safety profile," Mateos said in a statement. "These results support BVd triplet therapy as a potential new standard of care option for these patients."
One author disclosed ties to pharmaceutical companies, including GlaxoSmithKline, which manufactures belamaf and funded the study.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted February 2024
Read this next
Persistent Sociodemographic Differences Seen in Use of AutoHCT for Multiple Myeloma
WEDNESDAY, May 8, 2024 -- Sociodemographic differences persist in utilization of autologous hematopoietic cell transplantation (autoHCT) for multiple myeloma, according to a study...
FDA Approves Abecma for Relapsed, Refractory Multiple Myeloma
TUESDAY, April 9, 2024 -- The U.S. Food and Drug Administration has approved Abecma (idecabtagene vicleucel) as a personalized CAR T-cell therapy for triple-class exposed relapsed...
Survival 21 Percent a Year After ICU Discharge for Blood Cancer Patients
THURSDAY, March 21, 2024 -- For hematologic malignancy (HM) patients admitted to the intensive care unit (ICU), survival is 49 percent at seven days and 21 percent at 12 months...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.